Doxorubicin News and Research RSS Feed - Doxorubicin News and Research

Doxorubicin hydrochloride is approved for use with other drugs as adjuvant therapy for breast cancer that has spread to the lymph nodes, including cancer that is HER-2 positive or has spread after surgery.

In addition to the uses that have been approved by the FDA, doxorubicin hydrochloride is sometimes used alone or with other drugs to treat other types of cancer. The drug continues to be studied in the treatment of many types of cancer.
FDA approves new combo treatment for patients with advanced sarcomas

FDA approves new combo treatment for patients with advanced sarcomas

There are approximately 15,000 sarcoma cases annually in the United States, comprising more than 60 types of soft tissue sarcomas and 20 types of bony sarcomas. [More]
NUS researchers identify molecular switch that makes breast cancer cells more aggressive

NUS researchers identify molecular switch that makes breast cancer cells more aggressive

A team of scientists from the National University of Singapore (NUS) has established novel insights into the relationship between breast cancer tumour intracellular redox environment and the cancer cells' ability to become invasive. [More]
Heart problems from common cancer treatment can be alleviated by using gene therapy

Heart problems from common cancer treatment can be alleviated by using gene therapy

Researchers of the Wihuri Research Institute and the University of Helsinki, Finland, have found that some of the harmful effects of a commonly used cancer drug can be alleviated by using gene therapy that stimulates blood vessel growth in the heart. [More]
Scientists find new way to see where certain cancer drugs accumulate in the body

Scientists find new way to see where certain cancer drugs accumulate in the body

Nanomedicine has the potential to help personalize cancer treatments and reduce side effects of therapeutic drugs. [More]
FDA approves new therapy for initial treatment of soft tissue sarcoma

FDA approves new therapy for initial treatment of soft tissue sarcoma

The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. [More]
New type of nanoparticles can deliver chemotherapy efficiently to cancer cells

New type of nanoparticles can deliver chemotherapy efficiently to cancer cells

Engineering researchers at The University of Texas at Austin have developed a new method that delivers chemotherapy directly and efficiently to individual cells. [More]
Research identifies potential treatment target for chemoresistant cancer cells

Research identifies potential treatment target for chemoresistant cancer cells

A team of researchers has discovered that chemoresistant lung cancer cells suppress immune functions and strengthen resistance to chemotherapy by producing interleukin-34 (IL-34)—a type of cytokine. [More]
Multifunctional nanocapsules could enhance drug delivery to specific disease sites

Multifunctional nanocapsules could enhance drug delivery to specific disease sites

A nanoparticle-based drug delivery system that can sense and respond to different conditions in the body, as well as to an externally applied magnetic field, could enhance doctors’ ability to target drugs to specific sites of disease. [More]
Nanoparticles shaped like rods and worms could effectively deliver drugs, research suggests

Nanoparticles shaped like rods and worms could effectively deliver drugs, research suggests

When it comes to delivering drugs, nanoparticles shaped like rods and worms are the best bet for making the daunting journey to the centre of a cell, new Australian research suggests. [More]
Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Researchers identify higher risk of early chemotherapy-related death in older patients with DLBCL

Although diffuse large B-cell lymphoma (DLBCL) is a curable disease in most patients aged 65 years or older, these patients are also at higher risk of chemotherapy-related death within the first 30 days of treatment. [More]
Edible ginger-derived nano-lipids could effectively deliver drugs for treating colon cancer

Edible ginger-derived nano-lipids could effectively deliver drugs for treating colon cancer

Edible ginger-derived nano-lipids created from a specific population of ginger nanoparticles show promise for effectively targeting and delivering chemotherapeutic drugs used to treat colon cancer, according to a study by researchers at the Institute for Biomedical Sciences at Georgia State University, the Atlanta Veterans Affairs Medical Center and Wenzhou Medical University and Southwest University in China. [More]
Nebivolol treatment may protect against antracycline-induced cardiotoxicity in breast cancer patients

Nebivolol treatment may protect against antracycline-induced cardiotoxicity in breast cancer patients

Nebivolol prevents anthracycline-induced cardiotoxicity, according to research presented at ESC Congress 2016 today by Professor Mirela Cleopatra Tomescu, a cardiologist at Victor Babes University of Medicine and Pharmacy, Timisoara, Romania. [More]
Researchers find promising new therapy for both pediatric and adult cancers

Researchers find promising new therapy for both pediatric and adult cancers

A study conducted at Nationwide Children's Hospital has found that a new chemotherapy is effective against both pediatric and adult cancers, and that it allows other chemotherapies to more readily reach their targets. [More]
Salmonella protein can reduce drug resistant molecule found in cancer cells

Salmonella protein can reduce drug resistant molecule found in cancer cells

A surprising result in an experiment on Salmonella bacteria has led to a discovery that may make drug resistant cancer cells more treatable by conventional chemotherapies. [More]
Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding a novel monoclonal antibody therapy to traditional chemotherapy increased median survival by nearly a year in patients with advanced sarcoma, a lethal soft-tissue cancer. [More]
Researchers propose new approach to target chemotherapy medications specifically to sarcomas

Researchers propose new approach to target chemotherapy medications specifically to sarcomas

Sarcoma is an aggressive form of cancer responsible for up to 20 percent of childhood cancers. Tumors often first appear in the extremities and the abdomen. Surgery is a primary treatment, but it often is combined with chemotherapy. [More]
Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. [More]
New drug-capture device can soak up chemotherapy drugs to limit toxicity

New drug-capture device can soak up chemotherapy drugs to limit toxicity

Doctors have a powerful arsenal of cancer-fighting chemotherapy drugs to choose from, though a key challenge is to better target these drugs to kill tumors while limiting their potentially harmful side effects. [More]
EAD therapy can shrink size of triple-negative breast cancer tumors in mice

EAD therapy can shrink size of triple-negative breast cancer tumors in mice

In a new study using mice and lab-grown human cells, a scientific team led by Johns Hopkins Kimmel Cancer Center researchers show how a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer cells and halting new tumor growth. [More]
New drug combination before surgery may improve outcomes in breast cancer patients

New drug combination before surgery may improve outcomes in breast cancer patients

Results from the I-SPY 2 trial show that giving patients with HER2-positive invasive breast cancer a combination of the drugs trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab. [More]
Advertisement
Advertisement